

**May 2016 P&T Committee Meeting—Table of Implementation Status of UF Recommendations/Decisions Summary**

Date	DoD PEC Drug Class	Type of Action	UF Medications	Nonformulary Medications  MTFs may not have on formulary	Decision Date / Implement Date	PA and QL Issues	Comments
May 2016	<b>Atypical Antipsychotics (AAPs)</b>	UF class review (previously reviewed May 2011)	<ul style="list-style-type: none"> <li>▪ risperidone, risperidone ODT</li> <li>▪ quetiapine IR</li> <li>▪ quetiapine ER (Seroquel XR)</li> <li>▪ aripiprazole tablets</li> <li>▪ aripiprazole ODT and oral solution</li> <li>▪ olanzapine</li> <li>▪ olanzapine/fluoxetine</li> <li>▪ ziprasidone</li> <li>▪ paliperidone</li> <li>▪ lurasidone (Latuda)</li> </ul>	<ul style="list-style-type: none"> <li>▪ asenapine (Saphris)</li> <li>▪ iloperidone (Fanapt)</li> <li>▪ brexpiprazole (Rexulti)</li> <li>▪ cariprazine (Vraylar)</li> </ul>	Pending signing of the minutes / 90 days	<ul style="list-style-type: none"> <li>▪ Manual PA applies to new and current users of brexpiprazole approved Feb 2016</li> </ul>	<ul style="list-style-type: none"> <li>▪ lurasidone added to the UF</li> <li><u>Rexulti UUs Affected</u> <ul style="list-style-type: none"> <li>▪ Retail: 1,436</li> <li>▪ Mail Order: 366</li> <li>▪ MTF: 45</li> <li><b>Total: 1,847</b></li> </ul> </li> <li><u>Vraylar UUs Affected</u> <ul style="list-style-type: none"> <li>▪ Retail: 2</li> <li>▪ Mail Order: 1</li> <li>▪ MTF: 0</li> <li><b>Total: 3</b></li> </ul> </li> </ul>
May 2016	<b>Contraceptives: Emergency Contraceptives</b>	UF class review (previously reviewed Aug 2011)	<ul style="list-style-type: none"> <li>▪ levonorgestrel 1.5mg (Plan B One Step, generics)</li> <li>▪ levonorgestrel 0.75mg (Plan B, generics)</li> <li>▪ ulipristal acetate 30mg (Ella)</li> </ul>	<ul style="list-style-type: none"> <li>▪ None</li> </ul>	Pending signing of the minutes	▪N/A	▪N/A
May 2016	<b>Anticonvulsant and Anti-Mania Drugs</b>	UF class review	<ul style="list-style-type: none"> <li>▪ carbamazepine tabs, chewable tabs, oral susp (Tegretol, generics)</li> <li>▪ carbamazepine ER tabs (Tegretol XR, generic)</li> <li>▪ divalproex (Depakote, Depakote ER, Depakote Sprinkles, generics)</li> <li>▪ phenytoin ER caps, chewable tabs, oral suspension (Dilantin, Dilantin-125, generics)</li> <li>▪ carbamazepine ER capsules (Carbatrol, generics)</li> <li>▪ carbamazepine ER (Equetro XR)</li> <li>▪ clobazam (Onfi)</li> <li>▪ Divalproex IR, ER and delayed release (Depakote, Depakote ER, Depakote Sprinkles, generics)</li> <li>▪ eslicarbazepine (Aptiom)</li> <li>▪ ethosuximide (Zarontin, generics)</li> <li>▪ felbamate (Felbatol, generics)</li> <li>▪ lacosamide (Vimpat)</li> <li>▪ lamotrigine IR, ER, chewable tabs (Lamictal, Lamictal XR,</li> </ul>	<ul style="list-style-type: none"> <li>▪ None</li> </ul>	Pending signing of the minutes	▪N/A	No change to PA for Trokendi and Qudexy XR from August 2014

Date	DoD PEC Drug Class	Type of Action	UF Medications	Nonformulary Medications  MTFs may not have on formulary	Decision Date / Implement Date	PA and QL Issues	Comments
			<ul style="list-style-type: none"> <li>Lamictal CD, generics) <ul style="list-style-type: none"> <li>▪ lamotrigine orally dissolving tablets (Lamictal ODT)</li> <li>▪ levetiracetam IR, ER, (Keppra; Keppra XR, generics)</li> <li>▪ oxcarbazepine (Trileptal, generics)</li> <li>▪ oxcarbazepine ER (Oxtellar XR)</li> <li>▪ perampanel (Fycompa)</li> <li>▪ phenytoin (Dilantin, generics)</li> <li>▪ phenobarbital (Luminol, generics)</li> <li>▪ primidone (Mysoline, generics)</li> <li>▪ rufinamide (Banzel)</li> <li>▪ topiramate IR and sprinkle (Topamax, Topamax Sprinkle, generics)</li> <li>▪ topiramate ER (Trokendi XR)</li> <li>▪ topiramate ER (Qudexy XR)</li> <li>▪ valproic Acid (Depakene, generics)</li> <li>▪ vigabatrin (Sabril)</li> <li>▪ zonisamide (Zonegran, generics)</li> </ul> </li> </ul>				

Date	DoD PEC Drug Class	Type of Action	UF Medications	Nonformulary Medications MTFs may not have on formulary	Decision Date / Implement Date	PA and QL Issues	Comments
May 2016	Renin-Angiotensin Anti-Hypertensive Agents (RAAs)	New Drugs  Class previously reviewed Aug 2010	<p><b>ARB/Neprilysin Inhibitor</b></p> <ul style="list-style-type: none"> <li>sacubitril/valsartan (Entresto)</li> </ul> <p><b>ACE Inhibitors</b></p> <ul style="list-style-type: none"> <li>benazepril +/- HCTZ</li> <li>captopril/HCTZ</li> <li>enalapril +/-HCTZ)</li> <li>fosinopril+/- HCTZ</li> <li>moexipril +/- HCTZ</li> <li>perindopril</li> <li>quinapril+/- HCTZ</li> <li>trandolapril +/- verapamil SR</li> </ul> <p><b>ACE Inhibitors</b></p> <ul style="list-style-type: none"> <li>lisinopril +/- HCTZ</li> <li>captopril</li> <li>ramipril</li> </ul> <p><b>ACE-Inhibitor/CCB</b></p> <ul style="list-style-type: none"> <li>benazepril/amlodipine</li> </ul> <p><b>ARBs</b></p> <ul style="list-style-type: none"> <li>losartan +/- HCTZ</li> <li>valsartan +/- HCTZ</li> </ul> <p><b>RAAs/CCB</b></p> <ul style="list-style-type: none"> <li>telmisartan/amlodipine (Twynta)</li> <li>olmesartan/amlodipine (Azor)</li> <li>valsartan/amlodipine (Exforge)</li> <li>valsartan/amlodipine/HCTZ (Exforge HCT)</li> </ul> <p><b>Direct Renin Inhibitors</b></p> <ul style="list-style-type: none"> <li>aliskiren (Tekturna)</li> <li>aliskiren/HCTZ (Tekturna HCT)</li> </ul>	<p><b>DRI/CCB</b></p> <ul style="list-style-type: none"> <li>aliskiren/amlodipine (Tekamlo)</li> </ul> <p><b>ARB/CCB/HCTZ</b></p> <ul style="list-style-type: none"> <li>olmesartan/amlodipine/HCTZ (Tribenzor)</li> </ul>	Pending signing of the minutes 60 days	PA requirements – see Aug 2010 minutes	<p><b>Entresto PA required</b></p> <p><b>Step-therapy (automated PA)</b> with the following as the step-preferred drugs:</p> <ul style="list-style-type: none"> <li>ACE inhibitors</li> <li>losartan ±HCTZ</li> <li>telmisartan ±HCTZ</li> <li>telmisartan/amlodipine</li> <li>valsartan ±HCTZ</li> <li>valsartan/amlodipine</li> <li>valsartan/amlodipine/HCTZ</li> </ul> <p><u>Entresto UUs Affected</u></p> <ul style="list-style-type: none"> <li>Retail: 440</li> <li>Mail Order: 516</li> <li>MTF: 97</li> <li><b>Total: 1,053</b></li> </ul>

Date	DoD PEC Drug Class	Type of Action	UF Medications	Nonformulary Medications MTFs may not have on formulary	Decision Date / Implement Date	PA and QL Issues	Comments
May 2016	<b>GI-2 Miscellaneous Drug Subclass</b>	New Drug  Class previously reviewed Nov 2015	<ul style="list-style-type: none"> <li>▪ metronidazole 250 mg and 500 mg tablets</li> <li>▪ alosetron (Lotronex)</li> <li>▪ fidaxomicin (Dificid)</li> <li>▪ linaclotide (Linzess)</li> <li>▪ lubiprostone (Amitiza)</li> <li>▪ nitazoxanide (Alinia)</li> <li>▪ rifaximin (Xifaxan)</li> <li>▪ tegaserod (Zelnorm) – discontinued</li> <li>▪ metronidazole (Flagyl, generics)</li> <li>▪ neomycin</li> <li>▪ vancomycin</li> </ul>	<b>May 2016</b> <ul style="list-style-type: none"> <li>▪ <b>Eluxadoline (Viberzi)</b></li> </ul>	Pending signing of the minutes / 90 days	<ul style="list-style-type: none"> <li>▪ Manual PA applies to new and current users of eluxadoline approved Feb 2016</li> </ul>	<ul style="list-style-type: none"> <li>▪ Viberzi PA updated</li> <li><u>Viberzi UUs Affected</u></li> <li>▪ Retail: 485</li> <li>▪ Mail Order: 114</li> <li>▪ MTF: 3</li> <li>▪ <b>Total: 602</b></li> </ul>

May 2016 Drugs with Prior Authorization Criteria

Unique Utilizers Affected per Drug				
	MTF	Mail Order	Retail	Total
<b>Amrix</b>	128	408	938	<b>1,474</b>
<b>Bystolic</b>	1,814	20,817	9,289	<b>31,920</b>
<b>Duexis</b>	13	537	912	<b>1,462</b>
<b>Ibrance</b>	54	185	322	<b>561</b>
<b>Movantik</b>	160	918	2,207	<b>3,285</b>
<b>Rytary</b>	20	425	282	<b>727</b>
<b>Vimovo</b>	30	1,104	828	<b>1,962</b>

UU: Unique Utilizers